Diminished Ovarian Reserve (DOR)

Diminished ovarian reserve means the ovaries hold fewer eggs than expected for a woman's age, and they tend to respond less strongly to fertility medication. It is a measure of egg quantity and how the ovaries are likely to behave during IVF stimulation, not a diagnosis of infertility.

Every woman is born with all the eggs she will ever have, and that number falls steadily over the years. DOR describes a faster or earlier decline than the typical pattern. The ovaries still work and ovulation often continues, so many women with DOR conceive naturally or with treatment.

One important point upfront. Reserve tests describe the size of the egg pool. They do not, on their own, predict whether you can get pregnant naturally, which is why context and a careful evaluation matter more than a single number.

DOR is about how many eggs remain and how the ovaries respond to stimulation, not a verdict on whether you can conceive. Low AMH or a low antral follicle count signals fewer eggs, but the ASRM notes these markers only weakly predict natural pregnancy.

Age is the single biggest driver of diminished ovarian reserve. The egg pool shrinks throughout adult life, and the decline speeds up after the mid-30s, so reserve naturally falls even in healthy women.

Several other factors can lower reserve earlier than expected. Genetic causes include the FMR1 (fragile X) premutation, which carries a recognised link to reduced ovarian reserve. Surgery on the ovaries, such as removing endometriomas or cysts, can remove healthy tissue along with the problem area. Cancer treatment with chemotherapy or pelvic radiation is toxic to eggs and is a well-known cause.

In a large share of cases, no clear reason is found. This is called idiopathic DOR, and it can affect younger women with no obvious risk factor, which is why testing is offered when fertility is a concern.

Diminished ovarian reserve usually has no symptoms at all. Most women feel completely normal and only learn about it through fertility testing, so the absence of any sign tells you nothing either way.

When changes do appear, the most common one is a shortening of the menstrual cycle. Periods that used to arrive every 28 to 30 days may start coming every 24 to 26 days, because the early-cycle hormone surge pushes ovulation a little earlier. Some women notice subtle shifts in flow or, much later, early signs that menopause is approaching.

Because the signs are so quiet, the trigger to test is often difficulty conceiving rather than any noticeable symptom.

DOR is diagnosed with a small set of tests that estimate the remaining egg pool. The ASRM identifies anti-Müllerian hormone (AMH) and the antral follicle count (AFC) as the most sensitive and reliable markers of ovarian reserve.

AMH is a blood test that can be done on any day of the cycle, and a low level points to a smaller egg pool. AFC is an early-cycle ultrasound that counts the small resting follicles in both ovaries. Day-3 FSH and estradiol, drawn on day 2 to 4 of the period, are older tests still used in many Indian clinics, where a high FSH suggests the ovaries are working harder to recruit eggs.

No single result confirms DOR. Doctors read these tests together, alongside age and history. Crucially, the ASRM cautions that reserve tests should not be used as a fertility test in women who are not already infertile.

Standard Diagnostic Tests in India

• Anti-Müllerian hormone (AMH) — A blood test taken on any cycle day. A low value points to a smaller pool of remaining eggs and is one of the two most reliable markers.
• Antral follicle count (AFC) — An early-cycle transvaginal ultrasound that counts the small resting follicles in both ovaries, giving a direct picture of reserve.
• Day-3 FSH and estradiol — Blood tests drawn on day 2 to 4 of the period. A high FSH suggests the ovaries are working harder to recruit eggs.
• Age and medical history — Doctors weigh your age, prior ovarian surgery, chemotherapy, and family history of early menopause alongside the lab results.
• Genetic testing when indicated — Screening for the FMR1 (fragile X) premutation may be offered, especially with unexplained early DOR or a relevant family history.

DOR mainly affects egg quantity and how the ovaries respond to fertility drugs, and the effect on natural fertility is often smaller than the test numbers suggest. The most direct consequence shows up during IVF, where fewer eggs are typically retrieved per cycle.

It helps to separate quantity from quality. A younger woman with low AMH still tends to have eggs of good quality for her age, so her chance per egg can stay reasonable. An older woman faces both a smaller pool and a higher rate of chromosomal errors in the eggs, which is why age matters more than AMH for the chance of a healthy pregnancy.

This response pattern is the basis of the ESHRE POSEIDON framework, which groups low-prognosis patients to help doctors set realistic expectations and tailor treatment. In a multinational POSEIDON study of over 13,000 ART patients, about 43% met low-prognosis criteria.

• Fewer eggs to work with: DOR mainly reduces egg quantity, so IVF cycles typically retrieve fewer eggs per stimulation.
• Quantity is not quality: A younger woman with low AMH often still has good-quality eggs, so her chance per egg can remain reasonable.
• Age drives quality: In older women, a smaller pool combines with more chromosomal errors in eggs, which lowers the live-birth chance.
• Variable IVF response: The ovaries may respond weakly to stimulation, the basis of the ESHRE POSEIDON low-prognosis groups used to tailor care.
• Natural conception still possible: Because ovulation often continues, many women with DOR conceive naturally or with simpler treatments.

Treatment for DOR focuses on making the most of the eggs that remain, and the right plan depends on your age, your goals, and how the ovaries respond. There is no medicine that grows new eggs or reverses the underlying reserve.

For couples trying naturally, timed intercourse and a prompt referral are reasonable when reserve is borderline and age is on your side. When IVF is chosen, doctors individualise the stimulation. Some women do better with tailored higher-dose protocols, while others benefit from gentler, mild-stimulation approaches that aim for fewer but good-quality eggs at lower cost and lower medication burden.

Supplements such as DHEA and CoQ10 are widely offered, but the evidence is mixed and far from conclusive. A 2023 network meta-analysis in Reproductive Biology and Endocrinology found possible benefits for poor responders while stressing low certainty, so they should be discussed as optional, not guaranteed. When a woman's own eggs are unlikely to work, donor eggs offer the highest success and are a recognised option under India's ART regulations.

With DOR, expect fewer eggs per IVF cycle and a more individualised plan, but remember that it only takes one healthy embryo. Your clinic will likely use the ESHRE POSEIDON approach to set realistic targets rather than chase a high egg count.

A few cycles may be needed to bank enough good embryos, and some women do better with milder protocols that reduce drug doses and cost. Egg freezing across more than one collection, sometimes called batching, is a common strategy. Cycles are occasionally cancelled if the ovaries do not respond, which is disappointing but not a failure of the whole plan.

Age remains the strongest predictor of success. If repeated cycles yield very few eggs or embryos, your doctor may discuss donor eggs early, since this honest conversation often shortens the road to a baby.